

Retraction of “Anticancer Effect of Rosiglitazone, a PPAR- γ Agonist against Diethylnitrosamine-Induced Lung Carcinogenesis”

Yanqiao Wu, Nagaraja Sreeharsha, Sanjay Sharma, Anurag Mishra,* Avinash Kumar Singh, and Shiva Kumar Gubbiyappa

ACS Omega 2020, 5 (10), 5334–5339, DOI: 10.1021/acsomega.9b04357




Cite This: *ACS Omega* 2021, 6, 33239–33239



Read Online

ACCESS |

 Metrics & More

 Article Recommendations

The Editors retract this Article due to concerns about the reliability and reproducibility of the published data. Concerns have been raised surrounding the experimental design including the comparison of animals treated with rosiglitazone. These concerns are significant enough to cast doubts on the main findings of the work.

The original Article was published on March 4, 2020, and retracted on November 19, 2021.

Received: November 3, 2021
Published: November 19, 2021

